The online version of this article (https://doi.org/10.1007/s40120-019-00154-7) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9741479.
A significant proportion of dementia is concretely estimated to be attributable to dementia with Lewy bodies (DLB)—one of the most common types of progressive dementia; however, there is a paucity of literature on this disease. We aimed to examine available evidence to gain a better understanding of its treatment landscape, clinical management, and disease burden.
A systematic literature review captured any DLB studies that report on randomised controlled trials (RCTs), epidemiology, disease progression, and economic data. An additional targeted literature review captured studies reporting on clinical management and quality of life (QoL) in this disease. Publication date was limited to 1 January 2007–26 March 2018, with the exception for RCTs, where no time restrictions were applied.
Of the 3486 studies initially identified, 55 studies were eligible for inclusion. The studies were mainly from Europe (n = 29), the USA (n = 9), and Japan (n = 8). Mini-Mental State Examination and Neuropsychiatric Inventory scores were the most commonly reported clinical outcomes in RCTs (n = 14). The most frequently identified interventions reported in RCTs were donepezil and memantine. Patients with DLB typically reported worse outcomes in relation to efficacy and safety, cognitive impairment, survival, and QoL compared with those with Alzheimer’s disease (AD). Additionally, patients with DLB were associated with higher hospitalisation rates and cost of care. Furthermore, there is a reliance on a small number of consensus guidelines. Of these, only one set of guidelines (DLB Consortium) was developed specifically for DLB.
The paucity of data indicates an unmet need in this therapy area. Although several studies look into the clinical and pathological aspects of DLB, consensus guidelines and studies on healthcare utilisation in patients with dementia have largely focused on AD. Additionally, most of the findings were made in comparison with AD.
Supplementary material 1 (DOCX 384 kb)40120_2019_154_MOESM1_ESM.docx
Mayo Clinic. Lewy body dementia. 2019. https://www.mayoclinic.org/diseases-conditions/lewy-body-dementia/symptoms-causes/syc-20352025. Accessed Apr 2019.
Cromarty RA, Elder GJ, Graziadio S, et al. Neurophysiological biomarkers for Lewy body dementias. Clin Neurophysiol. 2016;127(1):349–59.
Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. Brain Pathol. 2015;25(2):121–35.
Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13.
Woodard JS. Concentric hyaline inclusion body formation in mental disease analysis of twenty-seven cases. J Neuropathol Exp Neurol. 1962;21(3):442–9.
Kosaka K. Latest concept of Lewy body disease. Psychiatry Clin Neurosci. 2014;68(6):391–4.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24.
Papka M, Rubio A, Schiffer RB, Cox C. Lewy body disease: can we diagnose it? J Neuropsychiatry Clin Neurosci. 1998;10(4):405–12.
Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812–9.
Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014;6(2):21.
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683–97.
Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396–402.
Lewy Body Dementia Association (LBDA). Lewy body dementia: the state of the science. 2016. https://www.lbda.org/sites/default/files/2016_lbd_state_of_the_science_white_paper.pdf. Accessed 1 Apr 2019.
Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. http://handbook.cochrane.org. Accessed 1 Apr 2019.
Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.
Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.
Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.
Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and verbal episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies: a double-blind, placebo-controlled multicentre trial. Alzheimers Dement. 2013;9(4):P890.
Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46–54.
ClinicalTrials.gov. A post-marketing clinical study of aricept in patients with dementia with Lewy bodies (DLB). 2018. https://clinicaltrials.gov/ct2/show/NCT02345213. Accessed 1 Apr 2019.
Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4.
Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of phase III trial. Alzheimers Res Ther. 2015;7(1):5.
Mori E, Ikeda M, Kosaka K, Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52.
Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(2):67–73.
Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24(4):360–4.
Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13(3):183–92.
Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–63.
McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.
Rongve A, Soennesyn H, Skogseth R, et al. Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. BMJ Open. 2016;6(2):e010357.
Walker Z, McKeith I, Rodda J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer’s disease: a cohort study. BMJ Open. 2012;2(1):e000380.
Kramberger MG, Auestad B, Garcia-Ptacek S, et al. Long-Term cognitive decline in dementia with lewy bodies in a large multicenter, international cohort. J Alzheimers Dis. 2017;57(3):787–95.
Smits LL, van Harten AC, Pijnenburg YA, et al. Trajectories of cognitive decline in different types of dementia. Psychol Med. 2015;45(5):1051–9.
Kramberger MG, Olmo JG, Lemstra AW, et al. Clinical characteristics and course of DLB: results from a large longitudinal multicentre cohort. Alzheimers Dement. 2015;11(7):P320.
Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81(23):2032–8.
Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer’s disease. Eur J Neurol. 2009;16(2):212–7.
Stubendorff K, Hansson O, Minthon L, Londos E. Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer’s disease-measured from a fixed cognitive level. Dement Geriatr Cogn Disord. 2011;32(6):408–16.
Savica R, Ahlskog J, Boeve B, Bower J, Mielke M. Survival and risk of mortality of clinically-diagnosed synucleinopathies: a 15 year population-based study (1991–2005) (P3. 350). Neurology. 2016;86(16 Supplement):P3. 350.
Savica R, Bower J, Hagen C, Eric A, Mielke M. Survival and risk of mortality of synucleinopathies: a 15 years population-based study (1991–2005). Mov Disord. 2016;31:S157.
Price A, Farooq R, Yuan J-M, Menon VB, Cardinal RN, O’Brien JT. Mortality in dementia with Lewy bodies compared with Alzheimer’s dementia: a retrospective naturalistic cohort study. BMJ Open. 2017;7(11):e017504.
Matsui Y, Tanizaki Y, Arima H, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80(4):366–70.
Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390–8.
Bostrom F, Hansson O, Blennow K, et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2009;28(4):314–9.
Magierski R, Kloszewska I, Sobow TM. The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease. Neurol Neurochir Pol. 2010;44(2):139–47.
Meguro K, Kato Y, Chida K, Nakamura K, Nakatsuka M, Yamaguchi S. Effect of drug treatment and nursing home residency on life expectancy in dementia (DLB vs AD): a retrospective analysis in the Tajiri project. Alzheimers Dement. 2017;13(7):P385.
O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147–68.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88–100.
Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19(9):1159–79.
Boot BP, McDade EM, McGinnis SM, Boeve BF. Treatment of dementia with lewy bodies. Curr Treat Opt Neurol. 2013;15(6):738–64.
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):45.
Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435.
Galasko D. Lewy body disorders. Neurol Clin 2017;35(2):325–38.
Latoo J, Jan F. Dementia with Lewy bodies: clinical review. Br J Gen Pract. 2008;1(1):10–4.
Macijauskienė J, Lesauskaitė V. Dementia with lewy bodies: the principles of diagnosis, treatment, and management. Medicina. 2012;48(1):1–8.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.
Mueller C, Perera G, Rajamani A, et al. Risk and duration of hospitalization in dementia with Lewy bodies. Alzheimers Dement. 2017;13(7):P510–1.
Mueller C, Perera G, Rajkumar AP, et al. Hospitalization in people with dementia with Lewy bodies: frequency, duration, and cost implications. Alzheimers Dement (Amst). 2018;10:143–52.
Spears C, Besharat A, Martinez-Ramirez D, Almeida L, Armstrong M. Causes, complications and outcomes of hospitalization in patients with dementia with Lewy bodies [abstract]. Mov Disord 2017;32(suppl 2). https://www.mdsabstracts.org/abstract/causes-complications-and-outcomes-ofhospitalization-in-patients-with-dementia-with-lewy-bodies/. Accessed 6 Apr 2019.
Zhu CW, Scarmeas N, Stavitsky K, et al. Comparison of costs of care between patients with Alzheimer’s disease and dementia with Lewy bodies. Alzheimers Dement. 2008;4(4):280–4.
Boström F, Jönsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(8):713–9.
Vossius C, Rongve A, Testad I, Wimo A, Aarsland D. The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. Am J Geriatr Psychiatry. 2014;22(4):381–8.
Gustavsson A, Van Der Putt R, Jonsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer’s disease and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2009;24(10):1072–8.
Mougias AA, Politis A, Lyketsos CG, Mavreas VG. Quality of life in dementia patients in Athens, Greece: predictive factors and the role of caregiver-related factors. Int Psychogeriatr. 2011;23(3):395–403.
Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2011;32(4):227–34.
Bostrom F, Jonsson L, Minthon L, Londos E. Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):150–4.
Armstrong M, Monari E, Almeida L, McFarland N, Malaty I, Okun M. Initial patterns and correlates of quality of life in dementia with Lewy bodies (P6. 234). Neurology. 2016;86(16 Supplement):P6. 234.
Kurisu K, Terada S, Oshima E, et al. Comparison of QOL between patients with different degenerative dementias, focusing especially on positive and negative affect. Int Psychogeriatr. 2016;28(8):1355–61.
Figari-Jordan R, Anderson K, Gruber-Baldini A, et al. Comparison of quality of life and disability in three different dementias (P07. 180). Neurology. 2012;78(1 Supplement):P07. 180.
ClinicalTrals.gov. Study to evaluate the efficacy, safety and tolerability of E2027 in subjects with dementia with Lewy bodies. 2018. https://ClinicalTrials.gov/show/NCT03467152. Accessed 1 Apr 2019.
Price DL, Koike MA, Khan A, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease. Sci Rep. 2018;8(1):16165.
Bonanni L, Cagnin A, Agosta F, et al. The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurol Sci. 2017;38(1):83–91.
Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for medicare beneficiaries with Alzheimer’s. BMC Health Serv Res. 2008;8:108.
Taipale H, Purhonen M, Tolppanen AM, et al. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort. Scand J Public Health. 2016;44(2):150–8.
Phelan EA, Borson S, Grothaus L, Balch S, Larson EB. Association of incident dementia with hospitalizations. JAMA. 2012;307(2):165–72.
Leverenz JB. Global initiatives and future challenges. Alzheimers Dement. 2017;13(7):P1445.
- Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review
Amir Abbas Tahami Monfared
- Springer Healthcare
Neurology and Therapy
Print ISSN: 2193-8253
Elektronische ISSN: 2193-6536
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II